ArticleScientific reports2020
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 30 citations in OpenAlex.
- Pan-cancer analysis identifies APOC1 as a TAM-derived modulator of adaptive immune resistance and predictor of therapeutic response.Discover oncology · 2026Article
- Cancer-associated TRF1 mutations alter PARP1 interaction dynamics: an in silico study.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Development of a lactate metabolism signature for predicting homologous recombination repair status in breast cancer.Scientific reports · 2026Article
- Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present.Current oncology (Toronto, Ont.) · 2025Review
- Identifying somatic fingerprints of cancers defined by germline and environmental risk factors.Genetic epidemiology · 2024Article
- Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.British journal of cancer · 2024Article
- Article
- High Expression of MRE11A Is Associated with Shorter Survival and a Higher Risk of Death in CRC Patients.Genes · 2023Article
- Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer.International journal of molecular sciences · 2023Review
- Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.NPJ precision oncology · 2023Article
- Review
- Mechanisms of PARP Inhibitor Resistance.Cancer treatment and research · 2023Article
- Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy.Biomedicines · 2022Review
- Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer.Saudi journal of biological sciences · 2022Article
- PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.Cancers · 2022Review
- OAS3 is a Co-Immune Biomarker Associated With Tumour Microenvironment, Disease Staging, Prognosis, and Treatment Response in Multiple Cancer Types.Frontiers in cell and developmental biology · 2022Article
- Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.Cancers · 2021Review
- The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.Journal of hematology & oncology · 2021Review
- A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) in patients with germline mutations of BRCA1/BRCA2 are associated with benefit from drugs targeting DNA damage response (DDR), but they account for only 5-7% of overall breast cancer. To define the characteristics of these tumors and also to identify tumors without BRCA mutation but with homologous recombination deficiency (HRD) is clinically relevant. To define characteristic features of HRD tumors and analyze the correlations between BRCA1/BRCA2 and BC subtypes, we analyzed 981 breast tumors from the TCGA database using the signature analyzer. The BRCA signature was strongly associated with the HRD score top 10% (score ≥ 57) population. This population showed a high level of mutations in DDR genes, including BRCA1/BRCA2. HRD tumors were associated with high expression levels of BARD1 and BRIP1. Besides, BRCA1/2 mutations were dominantly observed in basal and luminal subtypes, respectively. A comparison of HRD features in BC revealed that BRCA1 exerts a stronger influence inducing HRD features than BRCA2 does. It reveals genetic differences between BRCA1 and BRCA2 and provides a basis for the identification of HRD and other BRCA-associated tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.